Natural killer cell immunotherapy against multiple myeloma: Progress and possibilities

被引：12

作者：

Liu, Pan ^{[1
]}

Jin, Yanxia ^{[1
]}

Sattar, Haseeb ^{[2
]}

Liu, Hailing ^{[3
]}

Xie, Weiling ^{[1
]}

Zhou, Fuling ^{[1
,4
]}

机构：

[1] Wuhan Univ, Dept Hematol, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China

[2] Huazhong Univ Sci & Technol, Tongji Med Coll, Affiliated Hosp, Dept Clin Pharm,Wuhan Union Hosp, Wuhan, Hubei, Peoples R China

[3] Xi An Jiao Tong Univ, Dept Clin Hematol, Affiliated Hosp 2, Xian, Shaanxi, Peoples R China

[4] Hubei Key Lab Tumor Biol Behav, Wuhan, Hubei, Peoples R China

来源：

JOURNAL OF LEUKOCYTE BIOLOGY | 2018年 / 103卷 / 05期

基金：

中国国家自然科学基金;

关键词：

immunotherapy; multiple myeloma; natural killer cell; HLA CLASS-I; NK CELLS; MEDIATED LYSIS; MONOCLONAL-ANTIBODIES; CANCER-IMMUNOTHERAPY; BISPECIFIC ANTIBODY; THERAPEUTIC TARGET; ADOPTIVE TRANSFER; T-CELLS; ACTIVATION;

D O I：

10.1002/JLB.2RU0517-176RR

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Multiple myeloma (MM) is a complex aggressive mature B-cell malignancy. Although with the wide application of chemotherapy drugs, it remains incurable and the vast majority of patients relapse. Natural killer (NK) cells, also known as CD56(+)CD3(-) large granular lymphocytes, are cytotoxic innate immune cells against MM without prior sensitization steps. NK cell-based immunotherapy is extensively promising in a wide range of clinical settings. It is worthy of note that some novel drugs such as monoclonal antibodies (mAbs), proteasome inhibitors (PIs), and immunomodulators (IMiDs) directly or indirectly activate NK cells to enhance their antitumor activity, and the combined regimens significantly improve the prognosis of MM patients. In this review, we summarize recent findings that support a role for NK cells in the pathogenesis of MM and outline innovative approaches in the implementation of NK cell-based immunotherapy against MM. Review on NK cell dysfunction in patients with multiple myeloma.

引用

页码：821 / 828

页数：8

共 95 条

[71] An Anti-B Cell Maturation Antigen Bispecific Antibody for Multiple Myeloma [J].

Ramadoss, Nitya S. ;

Schulman, Andrew D. ;

Choi, Sei-hyun ;

Rodgers, David T. ;

Kazane, Stephanie A. ;

Kim, Chan Hyuk ;

Lawson, Brian R. ;

Young, Travis S. .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2015, 137 (16) :5288-5291

[72] Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells [J].

Ray, A. ;

Das, D. S. ;

Song, Y. ;

Richardson, P. ;

Munshi, N. C. ;

Chauhan, D. ;

Anderson, K. C. .

LEUKEMIA, 2015, 29 (06) :1441-1444

[73] Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin [J].

Remark, Romain ;

Alifano, Marco ;

Cremer, Isabelle ;

Lupo, Audrey ;

Dieu-Nosjean, Marie-Caroline ;

Riquet, Marc ;

Crozet, Lucile ;

Ouakrim, Hanane ;

Goc, Jeremy ;

Cazes, Aurelie ;

Flejou, Jean-Francois ;

Gibault, Laure ;

Verkarre, Virginie ;

Regnard, Jean-Francois ;

Pages, Olivier-Nicolas ;

Oudard, Stephane ;

Mlecnik, Bernhard ;

Sautes-Fridman, Catherine ;

Fridman, Wolf-Herman ;

Damotte, Diane .

CLINICAL CANCER RESEARCH, 2013, 19 (15) :4079-4091

[74] Immunotherapeutic approaches to treat multiple myeloma [J].

Roeven, Mieke W. H. ;

Hobo, Willemijn ;

Schaap, Nicolaas ;

Dolstra, Harry .

HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (04) :896-910

[75] Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants [J].

Ruggeri, L ;

Capanni, M ;

Urbani, E ;

Perruccio, K ;

Shlomchik, WD ;

Tosti, A ;

Posati, S ;

Rogaia, D ;

Frassoni, F ;

Aversa, F ;

Martelli, MF ;

Velardi, A .

SCIENCE, 2002, 295 (5562) :2097-2100

[76] Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A [J].

Sarkar, Subhashis ;

van Gelder, Michel ;

Noort, Willy ;

Xu, Yunping ;

Rouschop, Kasper M. A. ;

Groen, Richard ;

Schouten, Harry C. ;

Tilanus, Marcel G. J. ;

Germeraad, Wilfred T. V. ;

Martens, Anton C. M. ;

Bos, Gerard M. J. ;

Wieten, Lotte .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2015, 64 (08) :951-963

[77] ALTERED EXPRESSION OF P-GLYCOPROTEIN AND CELLULAR ADHESION MOLECULES ON HUMAN MULTI-DRUG-RESISTANT TUMOR-CELLS DOES NOT AFFECT THEIR SUSCEPTIBILITY TO NK-MEDIATED AND LAK-MEDIATED CYTOTOXICITY [J].

SCHEPER, RJ ;

DALTON, WS ;

GROGAN, TM ;

SCHLOSSER, A ;

BELLAMY, WT ;

TAYLOR, CW ;

SCUDERI, P ;

SPIER, C .

INTERNATIONAL JOURNAL OF CANCER, 1991, 48 (04) :562-567

[78] Immune parameters in multiple myeloma patients:: Influence of treatment and correlation with opportunistic infections [J].

Schuett, Philipp ;

Brandhorst, Dieter ;

Stellberg, Werner ;

Poser, Miriam ;

Ebeling, Peter ;

Mueller, Siemke ;

Buttkereit, Ulrike ;

Opalka, Bertram ;

Lindemann, Monika ;

Grosse-Wilde, Hans ;

Seeber, Siegfried ;

Moritz, Thomas ;

Nowrousian, Mohammad R. .

LEUKEMIA & LYMPHOMA, 2006, 47 (08) :1570-1582

[79] Antigen Presenting Cell-Mediated Expansion of Human Umbilical Cord Blood Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity [J].

Shah, Nina ;

Martin-Antonio, Beatriz ;

Yang, Hong ;

Ku, Stephanie ;

Lee, Dean A. ;

Cooper, Laurence J. N. ;

Decker, William K. ;

Li, Sufang ;

Robinson, Simon N. ;

Sekine, Takuya ;

Parmar, Simrit ;

Gribben, John ;

Wang, Michael ;

Rezvani, Katy ;

Yvon, Eric ;

Najjar, Amer ;

Burks, Jared ;

Kaur, Indreshpal ;

Champlin, Richard E. ;

Bollard, Catherine M. ;

Shpall, Elizabeth J. .

PLOS ONE, 2013, 8 (10)

[80] Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma [J].

Shi, Jumei ;

Tricot, Guido J. ;

Garg, Tarun K. ;

Malaviarachchi, Priyangi A. ;

Szmania, Susann M. ;

Kellum, Rachel E. ;

Storrie, Brian ;

Mulder, Arend ;

Shaughnessy, John D., Jr. ;

Barlogie, Bart ;

van Rhee, Frits .

BLOOD, 2008, 111 (03) :1309-1317

← 1 2 3 4 5 6 7 8 9 10 →